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Dominant TOM1 mutation associated with combined
immunodeﬁciency and autoimmune disease
Salla Keskitalo1, Emma M. Haapaniemi2,3,4, Virpi Glumoff5, Xiaonan Liu 1, Ville Lehtinen6, Christopher Fogarty7,8,9, Hanna Rajala10,11,
Samuel C. Chiang12, Satu Mustjoki10,11, Panu Kovanen13, Jouko Lohi13, Yenan T. Bryceson3, Mikko Seppänen 14, Juha Kere7,15,16,17,
Kaarina Heiskanen18 and Markku Varjosalo1
Mutations in several proteins functioning as endolysosomal components cause monogenic autoimmune diseases, of which
pathogenesis is linked to increased endoplasmic reticulum stress, inefﬁcient autophagy, and defective recycling of immune
receptors. We report here a heterozygous TOM1 p.G307D missense mutation, detected by whole-exome sequencing, in two related
patients presenting with early-onset autoimmunity, antibody deﬁciency, and features of combined immunodeﬁciency. The index
patient suffered from recurrent respiratory tract infections and oligoarthritis since early teens, and later developed persistent low-
copy EBV-viremia, as well as an antibody deﬁciency. Her infant son developed hypogammaglobulinemia, autoimmune enteropathy,
interstitial lung disease, profound growth failure, and treatment-resistant psoriasis vulgaris. Consistent with previous knowledge on
TOM1 protein function, we detected impaired autophagy and enhanced susceptibility to apoptosis in patient-derived cells. In
addition, we noted diminished STAT and ERK1/2 signaling in patient ﬁbroblasts, as well as poor IFN-γ and IL-17 secretion in T cells.
The mutant TOM1 failed to interact with TOLLIP, a protein required for IL-1 recycling, PAMP signaling and autophagosome
maturation, further strengthening the link between the candidate mutation and patient pathophysiology. In sum, we report here an
identiﬁcation of a novel gene, TOM1, associating with early-onset autoimmunity, antibody deﬁciency, and features of combined
immunodeﬁciency. Other patient cases from unrelated families are needed to ﬁrmly establish a causal relationship between the
genotype and the phenotype.
npj Genomic Medicine            (2019) 4:14 ; https://doi.org/10.1038/s41525-019-0088-5
INTRODUCTION
Primary immunodeﬁciencies that present with prominent auto-
immunity provide insights into the molecular mechanisms of
tolerance breakdown. The common defective genes in these
conditions encode proteins that affect T-cell development and
function. Examples include loss of FOXP3 that governs the
regulatory T-cell development, and gain or loss of the STAT
proteins that polarize T cells to different helper subsets.1–8 In
addition, defects in major immunological signaling molecules and
proteins that govern the actin cytoskeleton formation can lead to
T-cell driven autoimmunity.2,7
Several proteins functioning in the endolysosomal system can
also cause monogenic autoimmune diseases when defective9–11
(online Supplementary Information Table S1). The pathogenesis is
linked to increased endoplasmic reticulum stress, inefﬁcient
autophagy, and impaired recycling of immune receptors. Herein,
we report a previously undescribed, dominantly inherited immune
disease in two related patients that carry a missense mutation in
TOM1 (Target of Myb protein 1). TOM1 is an adaptor protein
needed for the maturation of autophagosomes and their fusion
with lysosomes.12 TOM1 also inhibits Toll-like receptor (TLR)
signaling and participates in immune receptor recycling.13,14
Clinically, the index patient presents with a relatively mild disease,
whereas in the child the condition is aggressive and fatal. This
phenotypic heterogeneity is common in monogenic immune
diseases and points to additional genetic modiﬁers in disease
presentation.
RESULTS
We evaluated a mother–son pair presenting with childhood-onset
autoimmune disease and combined immunodeﬁciency (Table 1,
and detailed case descriptions in Supplementary Information). The
index case (Patient 1, II.2) suffered from recurrent respiratory tract
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infections and joint pain since her early teens, and was diagnosed
with seronegative oligoarthritis and hypogammaglobulinemia at
age 16 (plasma IgG of 3,0 g/l, IgA 0,15 g/l, and IgM 0,17 g/l).
Intravenous immunoglobulin replacement was initiated but soon
discontinued due to adverse effects. In her early 30 s, she
developed chronic diarrhea with normal endoscopic ﬁndings
and was noted to have persistent low-copy EBV viremia, between
200–800 viral copies/ml. She is currently receiving peroral
prednisolone, methotrexate, and subcutaneous immunoglobulin
replacement.
Her son (Patient 2, III.1) was evaluated for failure to thrive at age
6 months and was subsequently diagnosed with autoimmune
enteropathy and lung disease that later evolved to lymphocytic
interstitial pneumonitis (LIP). At age 3, he developed eczema that,
by age 6, had become generalized and treatment resistant,
resembling psoriasis vulgaris (Supplementary Fig. S1). He dis-
played profound growth failure (–4.5 SD) and hypogammaglobu-
linemia since age 12 months. During the course of the study, he
received peroral tacrolimus, methotrexate and subcutaneous
immunoglobulin replacement, and recently underwent allogeneic
stem cell transplant, with a temporary resolution of autoimmune
symptoms. Within 6 months, however, he rejected the allograft
and the disease returned. He died one year after the transplant for
progressive pulmonary ﬁbrosis.
Detailed immunological workup is presented in online Supple-
mentary Information Tables S2 and S3. Both patients had low
numbers of dendritic cells, NK cells and switched memory B cells;
additionally, the regulatory T-cell function was impaired in the
severely affected son (Table 1 and Tables S2 and S3). The T-cell
compartment showed increased naive as well as decreased T-cell
effector memory (TEM) and effector memory RA (TEMRA) subsets,
suggesting impaired T-cell maturation. Both patients had poor
IFN-γ and IL-17 secretion upon stimulation, even though
enhanced Th17 response is considered a hallmark of T-cell-
mediated autoimmune disease.6
As the clinical presentation pointed to dominantly inherited
immunodeﬁciency, we performed trio-whole-exome sequencing
of the mother, the only child and his healthy father. We ﬁltered
the data for dominant coding sequence variants shared by the
affected individuals and not present in the public and in-house
control datasets. This resulted in 13 variants, of which three were
damaging to the protein structure and affected a conserved
residue (online Supplementary Information Table S4). A variant in
Target of Myb protein 1 -gene (TOM1; chr22: 35728994 G > A, p.
G307D, Fig. 1a) was considered the most likely candidate, as it was
absent from control datasets and deleteriously affected a
conserved residue (SIFT prediction “deleterious”, PolyPhen pre-
diction “probably damaging”). TOM1 is highly expressed in
immune cells and participates in autophagy, ubiquitination, and
receptor recycling; pathways, which are implicated in several
monogenic autoimmune conditions (refs 10,11 and Table S1).
The expression of WT and mutant TOM1 were identical (Fig. 1b
and Supplementary Fig. S1B); therefore, we hypothesized that the
mutation affects cellular protein–protein interactions of TOM1, as
is the case in many pathogenic missense variants that do not lead
to absent protein expression.15 Therefore, we used Flp-In T-REx
Table 1. Clinical and immunological features of the study participants
Patient 1, II.2 Patient 2, III.1
Sex Female Male
Current age 32 9
Growth Normal growth Growth failure (–4.5 SD)
Infection susceptibility
Respiratory tract infections Respiratory tract infections
Low-copy EBV viremia (100–2600 copies/ml)
Immune dysregulation
Atopic eczema Psoriasis
Seronegative polyarthritis Lymphocytic interstitial pneumonitis
Chronic diarrhea Autoimmune enteropathy
Laboratory featuresa
Lymphocytes (1300–3600) 660 ↓ 1670
B cells (CD19+ ) (100–500) 20 ↓ 320
Switched memory B cells (CD27+ IgD−IgM−) (6.5%–29.2%) 0 ↓ 0 ↓
T cells (CD3+ CD4+ ) (300–1400) 491 722
T cells (CD3+ CD8+ ) (200–1200) 170 ↓ 300
Treg (FOXP3+ CD25+ ) (2.8%–6.4%) 5.8 5.5
Treg suppressive capacity Normal Reduced
NK cells (CD3-CD16+ 56+ ) (90–600) 40 ↓ 20 ↓
Plasmacytoid dendritic cells (lin-HLA-DR+ CD123+ CD11c–) 0.04 ↓ 0.04 ↓
Monocytoid dendritic cells (lin-HLA-DR+ CD13–CD11c+ ) 0.04 ↓ 0.04 ↓
Immunoglobulins
IgG (6.8-15.0 g/l) 0.9 ↓ 7.5 (substitution)
IgA (0.52-4.02 g/l) 0 ↓ < 0.1 ↓
IgM (0.47-2.84 g/l) 0.07 ↓ 0.1 ↓
IgE (0-110 IU/l) < 4 5 kU/l
Child’s deviant values are indicated according to pediatric references
aSee Online Supplementary Information Tables S2 and 3 for more comprehensive workup
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293 cell lines that ectopically expressed mutant or wild type (WT)
streptavidin-tagged TOM1 and analyzed the interactions by
afﬁnity-puriﬁcation mass spectrometry (AP-MS). The AP-MS
analysis conﬁrmed the known and identiﬁed several novel
interactions (Fig. 1b). In the quantitative interactome analysis
the mutant TOM1 had statistically signiﬁcant decreased interac-
tions with ubiquitin C (2.8% mutant, 5.7% WT) and TOLLIP (11.2%
mutant, 22.0% WT) (Fig. 1c). TOLLIP is an endosomal protein that
negatively regulates TLR (toll-like receptor) and innate immune
signaling, and is associated with various autoimmune
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conditions.16 Normally upon transient co-expression TOLLIP
recruits TOM1 to endosomes,13 however this function was
impaired with the mutant TOM1 (Fig. 1c), although WT and
mutant TOM1 showed similar cytosolic localization (Supplemen-
tary Fig. S2). These data suggest that the mutation disrupts the
TOM1–TOLLIP complex formation, which then hampers the
packaging of ubiqitinylated proteins to endosomes.
To further understand how TOM1–TOLLIP complex functions in
endosomal cargo delivery, we performed BioID experiments with
stable Flp-In T-REx 293 cells lines. The BioID method involves bait-
fused modiﬁed biotin ligase (BirA) biotinylating close-proximity
proteins allowing identiﬁcation of transient and proximal interac-
tions.17 In this analysis TOM1 and TOLLIP localized to endo/
exosomal vesicles and had multiple common interaction partners.
As defects in the vesicular trafﬁcking protein LRBA cause
monogenic autoimmune disease similar to our patients,18 we
even mapped the interactions of this protein. LRBA interacted
with both TOM1 and TOLLIP but had molecular context mainly in
the Golgi/trans-Golgi transport. This suggests that while TOM1
localizes to vesicles, LRBA functions mainly in the Golgi-
endosomal axis, and the molecular pathogenesis of TOM1 and
LRBA deﬁciencies are distinct from each other (Supplementary Fig.
S2).
Ubiqitinylated proteins are degraded by the endolysosomal
system. The process is tightly connected to autophagy, in which
the cell digests its own organelles to create energy and nutrients.
To evaluate whether autophagy was disturbed in patient
lymphocytes, we analyzed the expression of LC3—which indicates
the presence of autophagosomes—after serum starvation (Fig.
1d). Lymphocytes from both patients showed decreased
LC3 staining, indicating a low autophagosome count compared
to a healthy control. Rapamycin and other rapalogs are potent
inducers of autophagy, and in an attempt to control autoimmunity
we treated patient 2 with everolimus. Contrary to our expecta-
tions, this led to ﬂares of eczema and respiratory distress,
symptoms that quickly stabilized once the drug was stopped. In
vitro, rapamycin treatment on patient lymphocytes failed to
increase the number of autophagosomes (Fig. 1e). These
observations point to impaired autophagy, most probably due
to defects in autophagosome formation.
As impaired autophagy often leads to increased apoptosis,19 we
also evaluated the proportion of apoptotic and dead PBMCs in the
patients, which were increased compared to healthy control (Fig.
1f). Similar phenotypes of increased apoptosis and defective
autophagy have been reported in common autoimmune condi-
tions such as systemic lupus erythematosus and in the monogenic
autoimmune disease caused by LRBA-deﬁciency.18,20 Impaired
autophagy is also linked to increased endoplasmic reticulum
stress;21 however, we did not detect evidence of abnormal ER
stress response when staining inﬂamed gut and respiratory
mucosa parafﬁn sections with BiP antibody.
Besides autophagy, TOM1 participates in receptor recycling.12,13
We therefore examined the patient lymphocytes for their ability to
express CTLA4, IL-1 and IL-6 receptors, as increased IL-6 signaling
and impaired CTLA-4 expression give monogenic autoimmune
phenotypes similar to our patients.6,22 All tests were normal
(Supplementary Fig. S2). To further understand the effect of the
mutation on major immune signaling pathways, we measured
activating phosphorylation of components of Jak-STAT, NF-κB, and
Ras-MAPK signaling pathways in patient skin ﬁbroblasts (Fig. 1g).
Interestingly, ERK1/2 phosphorylation was signiﬁcantly down-
regulated in both patients (log2 fold change > 1, Fig. 1g)
indicating dysfunctional MAPK signaling. Both patients also
showed impaired STAT1 and STAT5 tyrosine phosphorylation that
further diminished upon rapamycin treatment. Single-gene
defects in both of these STATs lead to early-onset autoimmunity
by disrupting T-cell development and polarization.1,4,5,8 These
results suggest that the TOM1 mutation affects MAPK and JAK-
STAT signaling. This most likely explains the observed Th1 and
Th17 cell developmental defects (Table S3) and contributes to
poor regulatory T-cell function.
DISCUSSION
We associate heterozygous TOM1 mutation to a combined
immunodeﬁciency and early-onset autoimmunity. The TOM1
mutation disrupts the TOM1–TOLLIP complex formation and the
patient cells show defects in autophagy, susceptibility to
apoptosis, and downregulation of multiple key signaling effectors,
including ERK1/2, STAT1, and STAT5. The difference in disease
severity suggest that additional genetic and environmental factors
modify the phenotype. As in all ultra-rare diseases initially
reported in single families, additional cases from unrelated
pedigrees are needed to determine with complete certainty a
causal relationship between mutations in TOM1 and the clinical
phenotype described here, and to better understand the
molecular pathogenesis of TOM1 mutations.23
METHODS
Study participants
The study was conducted in accordance to the principles of the Helsinki
Declaration and was approved by the Helsinki University Hospital Ethics
Committee. Written informed consent was obtained from the mother and
father, as well as their permission for the child. Also all other participants
signed written informed consent. The authors afﬁrm that human research
participants provided informed consent, for publication of the images in
the Supplementary Fig. S1.
Fig. 1 a Schematic representation of TOM1 and the observed mutation in the GAT (GGA and Tom1) domain. Mutated G307 residue and its
evolutionary conservation is shown together with predicted reduced stability (predicted pseudo ΔΔG). b The AP-MS analysis of TOM1 wild
type (WT), G307D mutant and TOLLIP WT conﬁrmed reciprocally the known interactions of TOM1 and TOLLIP (blue edges) as well as identiﬁed
several novel (red) interactions. The black dashed line indicates known prey-to-prey interactions. Inset: expression of all the constructs was
conﬁrmed with western blotting using anti-HA antibody. Tubulin was used as a loading control. Blots derive from the same experiment and
they were processed in parallel. c The quantitative interactome analysis of TOM1 WT (green) and G307D mutant (red) showed signiﬁcantly
decreased binding of the G307D with polyubiquitin-C (UBC) and TOLLIP compared to the WT. Error bars indicate standard deviation. The p-
values were calculated using Student’s t-test. Inset: TOLLIP efﬁciently recruits TOM1 WT (left) to early endosomes while recruitment of G307D
(right) is hampered. HeLa cells were co-transfected with Myc-tagged WT or G307D TOM1 (green and red rectangle, respectively) and HA-
tagged TOLLIP. Merged images are shown, where scale bar represents 20 μm. d Diminished LC3 staining of patient PBMCs indicates decreased
autophagy. Son (III.1) is indicated with orange, mother (II.2) with blue, and control with red solid line. Interestingly, ~50% of son’s lymphocytes
overlapped with the unstained control population (black dashed line). MFI, mean ﬂuorescence intensity. e Rapamycin fails to induce
autophagy in PBMCs. Line colors indicate rapamycin concentrations. f PBMCs show elevated numbers of apoptotic and dead cells in both
patients. g Intracellular signaling network responses in patient skin ﬁbroblasts reveals alterations of key pathway components
phosphorylation levels at basal state and after rapamycin treatment. Heat map shows the calculated Log2 ratios of medians of panel/
channel values relative to untreated control. Analyzed phosphoepitopes were STAT1 (anti-pTyr701), p38 (anti-pThr180/pTyr192), S6 (anti-
pSer235/pSer236), STAT3 (anti-pTyr705), STAT5 (anti-pTyr694), and ERK1/2 (anti-pThr202/pTyr204)
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DNA extraction and whole-exome sequencing, and validation of
the candidate mutations
Genomic DNA was extracted from EDTA blood samples using Qiagen
FlexiGene DNA kit (Qiagen). Libraries were processed according to Agilent
SureSelect Target Enrichment System (Agilent Technologies) for Illumina
Paired-End Sequencing Library (Illumina) using SureSelect Human All Exon
V5 capture library (Agilent Technologies). Libraries were sequenced with
101 bp read length (HiSeq1500 sequencing platform, Illumina), with
~120x depth.
The read mapping, variant calling, and genome annotation were
performed as described previously.3 We ﬁrst analyzed the parent and
child exomes separately. After variant calling, we ﬁltered the data for
coding mutations with minor allele frequency of < 0.01 in control
databases (The Exome Aggregation Consortium (ExAC), 1000 Genomes,
NHLBI Exome variant server and UK TWIN and ALSPAC study cohorts (2–4),
as well as in-house databases. We then focused the search on rare,
damaging variants in known Mendelian disease-causing genes; however,
neither patient did have damaging variants with appropriate phenotype
and heritage model.
We next targeted the analysis on shared variants between the affected
individuals. We ﬁltered the data for shared coding mutations not present in
control databases (The Exome Aggregation Consortium (ExAC), 1000
Genomes, NHLBI Exome variant server and UK TWIN and ALSPAC study
cohorts (2–4), as well as in-house databases) (see Table S4). This analysis
recovered two functionally plausible candidate variants, one in TOM1 and
another in TBC1D31.
As the phenotype in the child was more severe than in the parent, we
also analyzed the data for damaging, coding variants that were
heterozygous in the mother, and homozygous or compound heterozygous
in the parent. No plausible variants were found.
The candidate mutations were veriﬁed by sequencing from ﬁbroblast
DNA and RNA/cDNA (Euroﬁns Genomics Germany GmbH, Germany) (Fig.
S1B). The mutant allele was expressed similarly to WT. Primers used for
sequencing (GAGGAGCTGCTCATCGTCAATG), forward primer for gDNA and
cDNA PCR (TOM1-forward1 CTGGAGCTCATCCCTCAGAT), reverse primer for
cDNA PCR (TOM1-reverse1 TACCTCTTTCCGTTGGTCAGC) and reverse
primer for gDNA PCR (TOM1-reverse2 AGCTGGGATGAGAGGTTGC).
B- and T-cell immunophenotyping
Fresh EDTA blood samples or PBMCs were used for B and T lymphocyte
immunophenotyping. Four or 6-color ﬂow cytometry panel with mAbs
against the surface antigens IgM, IgD, CD3, CD4, CD8, CD16⁄56, CD19,
CD21, CD27, CD33, CD34, CD38, CD45, CD56, CD57, CD133, HLA-DR, CD62L,
CD45RA, and CD45RO (BD Biosciences) were applied.24 The memory status
of T cells was studied with an antibody panel, including anti-CD45, -CD3,
-CD4, -CD45RA, and -CCR7 (R&D Systems).3,24
Evaluation of T-cell responses is described in detail elsewhere.24 For the
assessment of T-cell activation, fresh mononuclear cells were stimulated
for 6 h with anti-CD3, anti-CD28, and anti-CD49d (BD Biosciences). The cells
were analyzed using a 4- or 6-color ﬂow cytometry panel with mAbs
against the antigens CD45, CD3, CD4, CD8, CD16, CD56, CD45, CD45RA,
TCR-γ, CCR7, IFN-γ, and tumor necrosis factor (TNF).
Analysis of T- and NK-cell cytotoxicity
Evaluation of T- and NK-cell responses is described in detail elsewhere.24,25
For the assessment of T-cell activation and degranulation, fresh mono-
nuclear cells (MNCs) were stimulated for 6 h with anti-CD3, anti-CD28, and
anti-CD49d (BD Biosciences). For NK-cell degranulation, cytokine and
cytotoxicity assays, fresh MNCs or FACS-sorted CD3-CD16/56+ NK cells
were stimulated with K562 target cells for 6 h. The cells were analyzed
using 4- or 6-color ﬂow cytometry panel with mAbs against the antigens
CD45, CD3, CD4, CD8, CD16, CD56, CD45, CD45RA, TCRγ, CCR7, IFN-γ and
TNF-α. Additionally, standard 4 h chromium 51 (51Cr)-release assays were
performed according to established protocols for clinical samples using
magnetic bead—separated CD3+ CD8+ T cell or CD3−CD56+ NK cell
subsets.24,25
Phenotyping of Th17 and Treg cells
Phenotyping of IL-17-positive Th17 cells and Tregs is described in detail
elsewhere.3 Brieﬂy, fresh PBMCs were stimulated for 16 h with anti-CD3/
anti-CD28 beads in the presence of Brefeldin A. Thereafter, the cells were
ﬁxed, permeabilized and stained with anti-CD4, -CD69-APC, and IL-17A (BD
Biosciences) and analyzed with FACSAria II or FACSCanto II or LSRFortessa
ﬂow cytometer.
Th1/Th17 CD4+memory cells were detected from whole blood by a
four-color ﬂow cytometry panel with mAbs (CD45RA-FITC, CD4-PerCP,
CXCR3-APC, and CCR6-BV421 (BioLegend, San Diego, CA)) against surface
antigens similarly to ref. 26 eZKineTM Th1/Th17 Whole Blood Intracellular
Cytokine Kit (eBioSciences) was used to measure the INF-gamma
production.
Tregs were immunophenotyped from fresh blood with surface markers
against CD4, CD25, and FOXP3 (BD Biosciences).3 For evaluation of Treg
suppressor capacity, CD4+CD25+CD127- Treg cells were sorted from whole
blood using Human CD4+ T Cell Enrichment Cocktail (Stemcell Technol-
ogies) and ﬂuorescence-activated cell sorting with mAbs against CD4,
CD25, and CD127 (BD Biosciences). The cells were incubated for 6 days
with CFSE-labeled autologous responder T cells in a ratio of 1:2. Anti-CD3/
anti-CD28 beads (Life Technologies) were used as stimulus. CD4+ cells
were analyzed using FACSAria II ﬂow cytometer (BD Biosciences). The
suppression percentage was calculated with the following formula: 100 –
[(% proliferation in presence of Treg/% proliferation in absence of Treg)
x100].3,27
Generation of inducible Flp-In™ T-REx 293 cell lines
The cDNA constructs containing WT and p.G307D mutant TOM1 and LRBA
full length coding sequences were ordered as synthetic genes and cloned
into pTO_HA_StrepIII_c_GW_FRT,28 pTO_MYC_BirA_c,29 and pcDNA-
DEST40_3xV530 destination vectors. The TOLLIP cDNA was obtained as a
gateway compatible entry-clone and cloned into pTO_HA_Stre-
pIII_n_GW_FRT28 and pTO_MYC_BirA_n destination vectors. Generation
and culture of Flp-In T-REx 293 (ThermoFischerScientiﬁc) cell lines was
performed as previously described.28,31
Western blotting
For WB analysis, 5 × 105 Flp-In™ T-Rex 293 cells were seeded to six-well
plates, induced with tetracycline, harvested to Laemmli Sample Buffer,
boiled and ran to sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) gel. Proteins were transferred onto nitrocellulose
membrane and detected with anti-HA (HA-11, Covance), anti-V5 (Invitro-
gen), or anti-c-Myc primary (9E10, Santa Cruz) and horseradish peroxidase
(HRP)-conjugated secondary antibody. Anti-alpha Tubulin antibody
(ab7291, Abcam) was used as a loading control. Signal was visualized by
chemiluminescence.
Immunoﬂuorescence
Hela cells were seeded onto coverslips on four-well plates, transiently
transfected with Fugene6 (Promega) according to manufacturer’s instruc-
tions. The expression of the constructs was induced with tetracycline and
after 24 h the Hela cells were ﬁxed with 4% PFA. Cell were stained with
anti-HA antibody, anti-V5 antibody and visualized with Alexa-488 goat anti-
mouse IgG (Life Technologies, Thermo Fisher Scientiﬁc) or Alexa594 goat
anti-rabbit IgG. Nuclei were stained with DAPI prior to mounting with
Vectashield (Vector Laboratories). Fluorescent microscope, Zeiss Axio
Scope.A1 (Zeiss, Oberkochen, Germany) with x40 magniﬁcation was used
to image the samples. The image ﬁles were processed with Zen (Zeiss,
Oberkochen, Germany), CorelDRAW X7 and ImageJ softwares.
Afﬁnity puriﬁcation, BioID (puriﬁcation of BirA*), and mass
spectrometry
Afﬁnity puriﬁcation (AP) and BioID experiments together with mass
spectrometry were performed as previously described.29 Brieﬂy, for AP
~5 × 107 cells were lysed in HNN lysis buffer (50mM HEPES pH 8.0, 150mM
NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 1.5 mM Na3VO4, 1.0 mM PMSF
(phenylmethanesulfonylﬂuoride) and 10 μl/ml protease inhibitor cocktail,
Sigma). For BioID ~5 × 107 cells (5 × 15 cm dishes) in three biological
replicates were induced with 2 µg/ml doxycycline and 50 μM biotin for
24 h. After induction, cells were washed and harvested under harsher
conditions using 0.1% SDS and 80 U/ml Benzonase Nuclease (Santa Cruz
Biotechnology) in HNN lysis buffer. The proteins were bound using
Strep-Tactin sepharose and Bio-Spin chromatography columns (Bio-Rad)
and eluted with D-biotin (Thermo Scientiﬁc). After C18-puriﬁcation samples
were analyzed with Orbitrap Elite ETD hybrid mass spectrometer as
described in ref. 29 Each sample was analyzed in triplicates. The biological
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clustering and pathway analysis was conducted using DAVID bioinfor-
matics database.32
Small interfering RNA (siRNA) knock-down of TBC1D31
The ON-TARGETplus siRNA SMARTpool targeting human TBD1D31
(GUGAUGAUCUACAACGAAA, UGGCUGAAAUUGUUCGAUA, GCAGAUGCCU
AUAGACGAA, GAUAAAUGCGGCUGUAGAA) and the non-targeting pool
(UGGUUUACAUGUCGACUAA, UGGUUUACAUGUUGUGUGA, UGGUUUACA
UGUUUUCUGA, UGGUUUACAUGUUUUCCUA) (Dharmacon, USA) were
transfected to parental HAP1 cells (Horizon Discovery, UK) with Dharma-
FECT according to manufacturer’s protocols using recommended 100 nM
ﬁnal siRNA concentration. Twenty-four hour post transfection, the
transfection medium was replaced with normal complete medium. Cells
were analyzed for autophagy induction 48 h after transfection using
FlowCellect™ Autophagy LC3 Antibody-based Assay Kit (Merck Millipore).
For autophagy induction, the cells were either starved for 3 h (induced) or
left untreated (control).
Immunohistochemical staining of GRP78/BiP
Immunohistochemisty (IHC) of lung and duodenal biopsy parafﬁn sections
was performed according to standard techniques using GRP78/BiP mAb
(ab21685, Abcam). Biopsy slides from three healthy individuals (C1, C2, C3)
were used as controls.
CTLA4 staining of peripheral blood lymphocytes
Mononuclear cells puriﬁed from heparinized blood of the two patients and
two healthy controls (C4, C5) were stimulated either with CD3/CD28
Dynabeads (Invitrogen) and IL-2 (Proleukin), phytohemagglutinin and
Ionomycin, or growth media alone, for 5 days. Cells were then evaluated
for CTLA4 (Clone BNI3) expression in CD4+ T cells by ﬂow cytometry.
LC3 staining of peripheral blood mononuclear cells
Fresh PBMCs from the patients and three healthy controls (C6, C7, C8) were
incubated overnight in RPMI supplemented with 10% FCS and 1%
Penicillin–Streptomycin. To analyze the LC3 expression by FACS, the next
day cells were either serum-starved or let grow for 6 h. The LC3 staining
was done according to FlowCellect™ Autophagy LC3 Antibody-based Assay
Kit (Merck Millipore). The LC3 expression was measured according to kit
instructions using Guava easyCyte 6-2 L (Merck Millipore). All samples were
analyzed in triplicate.
Apoptosis assay
Fresh PBMCs from the patients and three healthy controls (C6, C7, C8) were
stained according to ViaCount® Reagent (Merck Millipore) instructions
immediately after isolation. The amount of viable, apoptotic and dead cells
was measured according to instructions using Guava easyCyte 6-2 L (Merck
Millipore).
Phospho-ﬂow analysis by mass cytometry
We performed skin biopsy to establish ﬁbroblast cell lines from both
patients and a healthy control (C9). Once established, the cells were
incubated for 16 h with 500 nM rapamycin or left untreated. The following
day cells were ﬁxed with paraformaldehyde, permeabilized with cold
methanol, and stained with Maxpar Signaling I Panel Kit according to
Maxpar Phoshophoprotein Staining Protocol provided by manufacturer
(Fluidigm). Data was collected on a CyTOF mass cytometer (Fluidigm). For
data analysis we utilized Cytobank premium (cytobank.org).
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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